Theravance Biopharma, Inc. Finance Lease, Right-of-Use Asset, Amortization
Theravance Biopharma, Inc. (TBPH) reported Finance Lease, Right-of-Use Asset, Amortization of $341.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2022-05-06
- Theravance Biopharma, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2022-03-31 was $341.00K, a 54.10% decline year-over-year.
- Theravance Biopharma, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2021-12-31 was $1.03M, a 9.11% decline year-over-year.
- Theravance Biopharma, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2021-09-30 was $1.01M, a 26.86% increase year-over-year.
- Theravance Biopharma, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2021-06-30 was $1.01M, a 4.78% increase year-over-year.
- Theravance Biopharma, Inc. finance lease, right-of-use asset, amortization for fiscal 2021 was $3.79M, a 13.22% increase from fiscal 2020.
- Theravance Biopharma, Inc. finance lease, right-of-use asset, amortization for fiscal 2020 was $3.34M, a 3.72% increase from fiscal 2019.
- Theravance Biopharma, Inc. finance lease, right-of-use asset, amortization for fiscal 2019 was $3.22M.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2022-03-31 | $341.00K 10-Q · filed 2022-05-06 | $1.37M derived: sum of 2 quarters · filed 2022-05-06 | $2.38M derived: sum of 3 quarters · filed 2022-05-06 | $3.38M derived: sum of 4 quarters · filed 2022-05-06 |
| 2021-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.03M derived: sum of 2 quarters · filed 2022-02-28 | $3.04M derived: sum of 3 quarters · filed 2022-02-28 | $3.79M 10-K · filed 2022-02-28 |
| 2021-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $2.02M derived: sum of 2 quarters · filed 2021-11-08 | $2.76M 10-Q · filed 2021-11-08 | $3.89M derived: sum of 4 quarters · filed 2022-05-06 |
| 2021-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.75M 10-Q · filed 2021-08-05 | $2.88M derived: sum of 3 quarters · filed 2022-05-06 | $3.68M derived: sum of 4 quarters · filed 2022-05-06 |
| 2021-03-31 | $743.00K 10-Q · filed 2022-05-06 | $1.87M derived: sum of 2 quarters · filed 2022-05-06 | $2.67M derived: sum of 3 quarters · filed 2022-05-06 | $3.63M derived: sum of 4 quarters · filed 2022-05-06 |
| 2020-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.92M derived: sum of 2 quarters · filed 2022-02-28 | $2.89M derived: sum of 3 quarters · filed 2022-02-28 | $3.34M 10-K · filed 2022-02-28 |
| 2020-09-30 | $793.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $1.76M derived: sum of 2 quarters · filed 2021-11-08 | $2.21M 10-Q · filed 2021-11-08 | $2.41M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $963.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $1.42M 10-Q · filed 2021-08-05 | $1.61M derived: sum of 3 quarters · filed 2022-02-28 | $2.63M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $457.00K 10-Q · filed 2021-05-06 | $652.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.67M derived: sum of 3 quarters · filed 2022-02-28 | $2.69M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.21M derived: sum of 2 quarters · filed 2022-02-28 | $2.24M derived: sum of 3 quarters · filed 2022-02-28 | $3.22M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $2.04M derived: sum of 2 quarters · filed 2020-11-09 | $3.03M 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $1.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $2.02M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $986.00K 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |